Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
This article was originally published in The Pink Sheet Daily
Executive Summary
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.
You may also be interested in...
Abbott Adds To Renal Pipeline In Deal With Action Pharma
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.
With Generous Partner Abbott Back For More, Reata Aims High Again
Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.
Reata Hopes To Beat Competition To Market With Abbott Deals
Reata Pharmaceuticals hopes the strength of its partnerships and intellectual property will allow it to get an edge on a hot market.